5-aza-N-methyl-1-methyl-4H,5H-benzo[h]furo[3,2-c]chromene-4,11-dione | 1211518-92-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 5-aza-N-methyl-1-methyl-4H,5H-benzo[h]furo[3,2-c]chromene-4,11-dione
• 英文别名: 8,14-Dimethyl-12,17-dioxa-8-azatetracyclo[8.7.0.02,7.011,15]heptadeca-1(10),2,4,6,11(15),13-hexaene-9,16-dione
• CAS: 1211518-92-1
• 化学式: C₁₆H₁₁NO₄
• 分子量: 281.268
• InChiKey: DWEIFLZZXNRFMQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  21
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  59.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-羟基-6-甲基-2H-吡喃[3,2-c]喹啉-2,5(6h)-二酮 、 一氯丙酮 在 ammonium acetate 、 溶剂黄146 作用下， 以 乙醇 、 甲苯 为溶剂， 反应 25.0h， 以50%的产率得到5-aza-N-methyl-1-methyl-4H,5H-benzo[h]furo[3,2-c]chromene-4,11-dione
  参考文献：
  名称：

  Antitumor Agents. 272. Structure−Activity Relationships and In Vivo Selective Anti-Breast Cancer Activity of Novel Neo-tanshinlactone Analogues

  摘要：

  Neo-tanshinlactone (1) and its previously reported analogues, such as 2, are potent and selective in vitro antibreast cancer agents. The synthetic pathway to 2 was optimized from seven to five steps, with a better overall yield. Structure-activity relationships studies on these compounds revealed some key molecular determinants for this family of antibreast agents. Several derivatives (19-21 and 24) exerted potent and selective antibreast cancer activity with IC50 values of 0.3, 0.2, 0.1, and 0.1 mu g/mL, respectively, against the ZR-75-1 cell lines. Compound 24 was 2- to 3-fold more potent than I against SK-BR-3 and ZR-75-1. Importantly, 21 exhibited high selectivity; it was 23 times more active against ZR-75-1 than MCF-7. Compound 20 had an approximately 12-fold ratio of SK-BR-3/MCF-7 selectivity. In addition, analogue 2 showed potent activity against it ZR-75-1 xenograft model, but not PC-3 and MDA-MB-231 xenografts, as well as high selectivity against breast cancer cell line compared with normal breast tissue-derived cell lines. Further development of lead compounds 19-21 and 24 as clinical trial candidates is warranted.

  DOI：

  10.1021/jm1000858

文献信息

• Antitumor Agents. 272. Structure−Activity Relationships and In Vivo Selective Anti-Breast Cancer Activity of Novel Neo-tanshinlactone Analogues
  作者：Yizhou Dong、Qian Shi、Huei-Chen Pai、Chieh-Yu Peng、Shiow-Lin Pan、Che-Ming Teng、Kyoko Nakagawa-Goto、Donglei Yu、Yi-Nan Liu、Pei-Chi Wu、Kenneth F. Bastow、Susan L. Morris-Natschke、Arnold Brossi、Jing-Yu Lang、Jennifer L. Hsu、Mien-Chie Hung、Eva Y.-H. P. Lee、Kuo-Hsiung Lee

  DOI：10.1021/jm1000858

  日期：2010.3.11

  Neo-tanshinlactone (1) and its previously reported analogues, such as 2, are potent and selective in vitro antibreast cancer agents. The synthetic pathway to 2 was optimized from seven to five steps, with a better overall yield. Structure-activity relationships studies on these compounds revealed some key molecular determinants for this family of antibreast agents. Several derivatives (19-21 and 24) exerted potent and selective antibreast cancer activity with IC50 values of 0.3, 0.2, 0.1, and 0.1 mu g/mL, respectively, against the ZR-75-1 cell lines. Compound 24 was 2- to 3-fold more potent than I against SK-BR-3 and ZR-75-1. Importantly, 21 exhibited high selectivity; it was 23 times more active against ZR-75-1 than MCF-7. Compound 20 had an approximately 12-fold ratio of SK-BR-3/MCF-7 selectivity. In addition, analogue 2 showed potent activity against it ZR-75-1 xenograft model, but not PC-3 and MDA-MB-231 xenografts, as well as high selectivity against breast cancer cell line compared with normal breast tissue-derived cell lines. Further development of lead compounds 19-21 and 24 as clinical trial candidates is warranted.